30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Barricaid Completes $52MM Financing to Support Barricaid -

Intrinsic Therapeutics completed a US $52MM Series Growth equity financing. Proceeds will support U.S. commercialization of the Barricaid® anular closure device, which is used after discectomy to treat herniated discs. In all, the company has raised ~$219MM in over 10 rounds of funding. The company received FDA Premarket Approval for Barricaid in 1Q19. (Intrinsic Therapeutics, Inc., 4/11/19)